id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2295469,503a8908-c2e3-481b-b88e-1ead61f1a6a4,2T,RED+BLUE STRATEGIES,400693064,CIGNA CORPORATION,2019,second_quarter,PHA,"Issues related to Trump Administration proposals and regulations regarding drug pricing reforms, regulations regarding rebates, and related guidances focused on affordability and accessibility to prescription medications in the United States. 

Proposals, guidances and call letters and impacting Medicare Part D and the role of Pharmacy Benefit Managers. 

Issues related to transparency in the prescription drug marketplaces including new technologies to improve physician and patient access to real time pricing questions and concerns. 

Issues related to utilization and access to e- prescribing tools. 

Issues focused on the promotion of fair competition in the prescription drug market place, including policies focused on patents, biosimilars and generic medications.",SENATE,20000,,0,1,2019-05-01T15:36:02.127000-04:00
2298640,654ca888-9145-4b8c-b9af-df6f5c31057f,Q2,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2019,second_quarter,PHA,Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2019-07-02T10:25:36.093000-04:00
2298732,5f53c9e6-1180-4fe7-b885-215d33f59cd5,Q2,"4C COMMUNICATIONS, INC.",323717,HEALTHCARE LEADERSHIP COUNCIL,2019,second_quarter,PHA,Discussion on pharmaceutical drug pricing,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2019-07-02T11:35:05.240000-04:00
2298943,81093bec-49c1-478f-a29c-f838c6f65ccc,Q2,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,401103437,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,2019,second_quarter,PHA,Compounding,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",,,0,0,2019-07-02T16:04:54.367000-04:00
2299238,fb931655-b239-4d2d-9578-cabb0e348eb3,Q2,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2019,second_quarter,PHA,Monitor Data and Science Policy.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",110000,,0,0,2019-07-03T12:19:29.370000-04:00
2299243,d267212c-dc2b-4ffe-b706-5484bfb3431f,2A,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2019,second_quarter,PHA,Monitor Data and Science Policy.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2019-07-03T12:31:31.197000-04:00
2299394,5228923d-353d-4158-a813-421829ac61d0,Q2,"RUBICON ADVISORS, LLC",315091,DYNAVAX TECHNOLOGIES,2019,second_quarter,PHA,Prescription Drug User Fee,"HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2019-07-03T15:48:39.267000-04:00
2299398,da389119-ede3-4e9e-b809-3d171f89d4f0,Q2,"RUBICON ADVISORS, LLC",315091,"DR. REDDY'S LABORATORIES, LTD",2019,second_quarter,PHA,Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues,"Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",45000,,0,0,2019-07-03T15:53:41.847000-04:00
2299399,6206c733-39f9-4922-811f-b7f4dfe16e4f,Q2,"RUBICON ADVISORS, LLC",315091,CONSCIOUS DISCIPLINE,2019,second_quarter,PHA,Medicare,"HOUSE OF REPRESENTATIVES,SENATE",37500,,0,0,2019-07-03T15:55:42.737000-04:00
2299620,9bae203a-1311-46ef-a966-5cea4d90f4cc,Q2,HOLLAND & KNIGHT LLP,18466,"TEVA PHARMACEUTICALS USA, INC.",2019,second_quarter,PHA,Drug pricing; Intellectual property.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2019-07-05T13:48:02.330000-04:00
2299908,1a1a2257-4aaa-44b0-9e22-7f508acf4af3,Q2,"POLITICAL CAPITAL, LLC",401104260,MEDISCA INC,2019,second_quarter,PHA,"Guidance documents, compounding pharmacy, appropriations language.","Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2019-07-08T13:30:39.493000-04:00
2299914,87613ae5-42dc-468b-980a-6ab611edd1f3,Q2,"POLITICAL CAPITAL, LLC",401104260,PINE PHARMACEUTICALS,2019,second_quarter,PHA,"Guidance documents, compounding pharmacy, appropriations language.","Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2019-07-08T13:37:42.853000-04:00
2299916,c331a9bf-8b5e-4837-96d0-790782e77b63,Q2,"POLITICAL CAPITAL, LLC",401104260,STOKES PHARMACY,2019,second_quarter,PHA,Compounding,"Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2019-07-08T13:38:43.447000-04:00
2299918,5d3094f8-96b9-40a3-9794-559d1f41d090,Q2,"POLITICAL CAPITAL, LLC",401104260,KRS GLOBAL BIOTECHNOLOGY INC,2019,second_quarter,PHA,Compounding,"Executive Office of the President (EOP),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2019-07-08T13:39:44.307000-04:00
2300051,3513e077-b0c3-4193-8f59-30b1f8fb00cb,Q2,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2019,second_quarter,PHA,"S. 1895 - The Lower Health Costs Act of 2019 - Issues related to the treatment of rebates in the prescription drug arena and transparency of information and data pertaining to the buying and selling of prescription medicines.

CREATES Act (S.340/ H.R. 965) - Issues related to reducing prices and increasing competition in the prescription drug marketplace.

C-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained. 

HHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits. 

Policies related to the reform of Medicare Part B and D specific to the price of prescription medications.","Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2019-07-08T20:27:44.267000-04:00
2300052,64ec0074-e5ea-4046-b9d5-148b3d507cc8,Q2,RED+BLUE STRATEGIES,400693064,PEW CHARITABLE TRUSTS,2019,second_quarter,PHA,"H.R. 2482 - The Mainstreaming Addition Treatment Act of 2019 - Support for policies increasing the ability to access MAT to treat addiction. 

H.R. 3443 - The OTC Monograph Safety Innovation and Reform Act of 2019 - Support for policies that enable OTC monograph reform. 

Issues related to the implementation on the SUPPORT Act (P.L. 115-271) regarding MAT treatment. 

Issues related to curbing antibiotic resistance.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2019-07-08T20:37:45.253000-04:00
2300801,1e036ea8-07a0-4277-b285-27e96923ff20,Q2,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,401103605,PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION,2019,second_quarter,PHA,"Discussed potential solutions for drug shortages, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers.","HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2019-07-10T10:58:10.707000-04:00
2300891,de96f6ca-f65d-41ac-8181-1b0d13829bb2,Q2,ACG ADVOCACY,2057,WALGREEN CO.,2019,second_quarter,PHA,"Drug Pricing Policy Issues.
Data privacy and DIR fee reform.","HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2019-07-10T12:18:08.027000-04:00
2301160,59077809-defa-4eb7-9a9e-7c3b3eb89892,Q2,"MARSHALL & POPP, LLC",401105121,"GENENTECH, INC.",2019,second_quarter,PHA,"Prescription drug value issues.

Biosimilars.

Importation of prescription drugs.

340B issues.

FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office",20000,,0,0,2019-07-10T16:37:43.237000-04:00
2301162,726e30b7-cf9c-4656-9ad5-8969cf73db37,Q2,"MARSHALL & POPP, LLC",401105121,"GENENTECH, INC.",2019,second_quarter,PHA,"Prescription drug value issues.

Biosimilars.

Importation of prescription drugs.

340B issues.

FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office",60000,,0,0,2019-07-10T16:38:44.113000-04:00
2301179,b18c0852-5932-487d-b51a-0f59c5868dbf,Q2,"MARSHALL & POPP, LLC",401105121,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2019,second_quarter,PHA,"Prescription drug value issues. 

Biosimilars. 

Importation of prescription drugs. 

340B issues. 

FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office",50000,,0,0,2019-07-10T16:52:54.943000-04:00
2301181,d79ecd4e-e44b-4d9e-ad14-a8e692be2322,Q2,"MARSHALL & POPP, LLC",401105121,"SANOFI U.S. SERVICES, INC.",2019,second_quarter,PHA,"Prescription drug value issues.

Biosimilars.

Importation of prescription drugs.

340B issues.

FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office",40000,,0,0,2019-07-10T16:56:55.787000-04:00
2301292,a0878609-ac72-4524-8e58-ad4f6ca46dde,Q2,RED+BLUE STRATEGIES,400693064,COHERUS BIOSCIENCES,2019,second_quarter,PHA,"S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. 

Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards.","Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),SENATE",60000,,0,0,2019-07-11T10:06:10.783000-04:00
2301336,24f41c09-609b-415c-998b-d28bd2562574,Q2,POLSINELLI PC,314911,"TEVA PHARMACEUTICALS USA, INC.",2019,second_quarter,PHA,"H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act
H.R.965/ S.340, CREATES Act
H.R.1503, Orange Book Transparency Act
H.R.1520, Purple Book Continuity Act
H.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act
H.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act
H.R.2376/ S.1227, Prescription Pricing for the People Act
S.1416, Affordable Prescriptions for Patients Act
S.1895, Lower Health Care Costs Act
H.R. 1499, Protecting Consumer Access to Generic Drugs Act
Administration review of drug pricing policies","HOUSE OF REPRESENTATIVES,SENATE",75000,,0,0,2019-07-11T10:40:32.103000-04:00
2301432,480e5332-57fc-4ec6-9c16-3df08929d923,Q2,MCDERMOTT+ LLC,401103287,ALLIANCE FOR RURAL HOSPITAL ACCESS,2019,second_quarter,PHA,Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2019-07-11T11:25:21.577000-04:00
2301504,64a4424d-470c-410a-9c80-5bdd0d5b3a45,Q2,JOHNSON MATTHEY INC.,401104441,JOHNSON MATTHEY INC.,2019,second_quarter,PHA,"H.R. 965 and S. 340 CREATES Act of 2019, provisions relating to improving the process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market.

H.R. 938 BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drugmakers challenging pharmaceutical patents.

S. 1895 Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drugmakers.

H.R. 990 and S. 344 Hatch-Waxman Integrity Act of 2019, provisions relating to limit generic companies' ability to initiate inter partes review.

H.R. 1520 Purple Book Continuity Act, provisions relating to codifying publication of patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book.

H.R. 1503 Orange Book Transparency Act, provisions relating to requiring manufacturers to share complete and timely information with FDA, as well as ensuring that patents listed in the Orange Book are relevant to the approved drug product.

H.R. 1499 Protecting Consumer Access to Generic Drugs Act, provisions relating to the prohibition of agreements between brand drug and generic manufacturers that pay generic manufacturers to keep the generic equivalent off the market.

H.R. 1781 Payment Commission Data, provisions relating to providing drug pricing and rebate data access the Medicare Payment Advisory Commission and Medicaid and CHIP Payment and Access Commission to help these commissions better understand the true costs of prescription drugs to consumers and taxpayers.","Environmental Protection Agency (EPA),HOUSE OF REPRESENTATIVES,SENATE",,20000,0,0,2019-07-11T12:26:55.100000-04:00
2301524,a20727ee-506e-4a11-9570-efe45f613793,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL HEMOPHILIA FOUNDATION,2019,second_quarter,PHA,"Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing programs.","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,0,2019-07-11T12:48:03.180000-04:00
2301927,0a447c8d-e561-4fe2-a80b-ee897d991957,Q2,"SIMS STRATEGIES, LLC",401104546,"GLAXOSMITHKLINE, INC.",2019,second_quarter,PHA,"Education and importance of various pharmaceutical industry issues, including issues affecting vaccines and shortages.",SENATE,40000,,0,0,2019-07-11T18:12:01.217000-04:00
2302060,f839166e-2a0f-4f97-8699-73e9b3eace56,Q2,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,312496,CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER,2019,second_quarter,PHA,"Drug pricing, PCORI re-authorization, 340B","Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office",,39050,0,0,2019-07-12T09:53:14.490000-04:00
2302083,b472c65c-87e4-47a6-9679-90bac0f04df1,Q2,MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP),24486,INOVIO PHARMACEUTICALS,2019,second_quarter,PHA,"Government Relations Services including developing strategies to achieve legislative goals, inclusion of MERS on list of neglected diseases at FDA","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2019-07-12T10:15:25.587000-04:00
2302482,7c5bd5d4-6a53-46f9-b45b-3712879730d8,Q2,HANCE SCARBOROUGH,17443,"TITAN PHARMACEUTICALS, INC.",2019,second_quarter,PHA,"Medicare/Medicaid drug coverage, opioid addiction policy.","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2019-07-12T14:12:03.647000-04:00
2302488,9d9b9fb0-8299-4284-bbcd-f964cb455000,Q2,HANCE SCARBOROUGH,17443,ALLIANCE FOR PHARMACY COMPOUNDING,2019,second_quarter,PHA,Issues related to the regulation of pharmacy compounding.  HR 1959 Preserving Patient Access to Compounded Medications Act.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2019-07-12T14:15:05.100000-04:00
2302825,0ec1ceb2-63d0-472f-83da-fa730683ca4a,Q2,340B HEALTH,316434,340B HEALTH,2019,second_quarter,PHA,The 340B Drug Pricing Program; FY 2020 L-HHS Appropriations.,"HOUSE OF REPRESENTATIVES,SENATE",,234868,0,0,2019-07-12T17:32:20.407000-04:00
2302894,24481571-ef25-443d-aa95-669c02c9e8b0,Q2,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2019,second_quarter,PHA,"Improving Transparency and Accuracy in Medicare Part D Spending Act S.988/ HR 803-IPC supports all pharmacy price concessions be reflected at the point-of-sale.
Proposed Regulation CMS-4180-P Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses. IPC supports.
Proposed Regulation - OIG-0936-P Fraud and Abuse Removal of Federal Social Security Act Safe Harbor Protections for Prescription Drug Manufacturer Rebates and Safe Harbor Protections for Prescription Drug Point-of-Sale Price Reductions-IPC supports if a reasonable timeline is given to implement.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2019-07-13T13:24:31.993000-04:00
2303003,c9e32859-57cc-40b4-a5f5-74e1b88cd3b3,Q2,"CONNECT 4 STRATEGIES, LLC",401103720,"OREXO US, INC.",2019,second_quarter,PHA,Medicare and Medicaid access,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2019-07-14T14:24:43.807000-04:00
2303006,d14a15af-81eb-4bed-8ea1-45ebe9daff98,Q2,"CONNECT 4 STRATEGIES, LLC",401103720,RECORDATI RARE DISEASES,2019,second_quarter,PHA,CMS Issues,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2019-07-14T14:35:45.950000-04:00
2303007,a586770b-16f2-46ba-8380-4b0324d2d0ba,Q2,"CONNECT 4 STRATEGIES, LLC",401103720,"AKCEA THERAPEUTICS, INC.",2019,second_quarter,PHA,FDA drug approval issues,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2019-07-14T14:39:46.793000-04:00
2303008,79a44dd6-4655-4c10-a5c6-30aba331ac8e,2A,"CONNECT 4 STRATEGIES, LLC",401103720,RECORDATI RARE DISEASES,2019,second_quarter,PHA,CMS Issues,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2019-07-14T14:43:47.577000-04:00
2303096,230f6dd5-d11f-4be6-bdbc-5c70a3c617f5,Q2,KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS),401105192,CVS HEALTH,2019,second_quarter,PHA,Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of health care. Issues related to the proposed CVS-Aetna merger.,HOUSE OF REPRESENTATIVES,45000,,0,0,2019-07-15T08:40:29.910000-04:00
2303233,d4198ab7-996a-4639-a39b-328a4e212db2,Q2,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION),2019,second_quarter,PHA,Issues related to drug pricing in the pharmaceutical supply chain.,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2019-07-15T11:04:32.583000-04:00
2303555,a179af30-ad8f-4053-8623-3259abffee7a,Q2,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,26672,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2019,second_quarter,PHA,"H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes

S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes

S.340 CREATES Act of 2019

H.R. 985 FAST Generics Act of 2019

S.640 Phair Pricing Act of 2019

S. 97 Affordable and Safe Prescription Drug Importation Act 

S. 61 Safe and Affordable Drugs from Canada Act of 2019

H.R. 1034 Phair Pricing Act of 2019

H.R. 965 CREATES Act of 2019

H.R. 1478 Affordable Insulin Act of 2019

H.R. 447 Affordable and Safe Prescription Drug Importation Act 

H.R. 1499 Protecting Consumer Access to Generic Drugs Act

H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019

H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019

H.R. 1607 Fairness to Pet Owners Act

H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act

H.R. 478 Safe and Affordable Drugs from Canada Act of 2019","HOUSE OF REPRESENTATIVES,SENATE",,400000,0,0,2019-07-15T13:25:27.187000-04:00
2303767,dc12826f-3363-4409-a808-47d781645549,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL ASSOCIATION OF EPILEPSY CENTERS,2019,second_quarter,PHA,Issues related to anti-epileptic drugs.,"Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",10000,,0,0,2019-07-15T14:58:46.683000-04:00
2303778,02cfcc66-7b5e-4d09-94b7-24e94e836b00,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,AMERICAN SOCIETY OF HEMATOLOGY,2019,second_quarter,PHA,"HR 1409, Cancer Drug Coverage Parity Act","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2019-07-15T15:00:50.497000-04:00
2303797,8ef8af19-4b5a-45d2-ae39-ff89555ef1c9,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,THE HEMOPHILIA ALLIANCE,2019,second_quarter,PHA,Issues related to the 340B drug discount program and drug pricing policies,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2019-07-15T15:03:54.277000-04:00
2303926,8713d6ba-50ec-474c-a3df-eb276796ef09,Q2,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY),2019,second_quarter,PHA,Issues related to the cost of care and protecting patient access to blood cancer treatment.  Issues related to specialty drug tiers.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2019-07-15T15:33:41.157000-04:00
2303990,520e45fa-396b-4eea-934d-6c179f5076a5,Q2,"NVG, LLC",76833,"MANATT, PHELPS AND PHILLIPS, LLP (ON BEHALF OF NEKTAR THERAPEUTICS)",2019,second_quarter,PHA,FDA oversight of certain pain reliever products.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2019-07-15T16:03:09.817000-04:00
2304356,05602b5f-97e4-48b1-a940-d79e18099e3e,Q2,LINCOLN PARK GROUP L.L.C.,401104374,CANADIAN INTERNATIONAL PHARMACY ASSOCIATION,2019,second_quarter,PHA,Support for S. 97/HR 447 Affordable and Safe Prescription Drug Importation Act and S. 61/HR 447 Safe and Affordable Drugs from Canada Act; issues related to personal drug importation.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2019-07-16T09:13:27.290000-04:00
2304590,e2ff7662-3e0f-40a0-83ae-a0dded12fc7c,Q2,"CARD & ASSOCIATES, LLC",84217,AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY),2019,second_quarter,PHA,"Educate Members on pharmacy contracting with pharmacy benefit managers
Monitoring legislation on drug price transparency and market access issues
S 1895 Lower Healthcare Costs Act
HR 2296 Fair Accountability and Innovative Research Drug Pricing Act
HR 2376 Prescription Pricing for the People Act","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2019-07-16T10:38:51.637000-04:00
2304749,95ffed18-b16f-4c5e-b3bd-1e7f6a19a10a,Q2,AMERICAN VETERINARY MEDICAL ASSOCIATION,3630,AMERICAN VETERINARY MEDICAL ASSOCIATION,2019,second_quarter,PHA,H.R.1607/S.1290 Fairness to Pet Owners Act,"HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE",,230000,0,0,2019-07-16T11:38:56.893000-04:00
2304812,543664dc-2a29-4721-aea6-174049919d09,Q2,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2019,second_quarter,PHA,"General issues related to over the counter pharmaceuticals.  Issues related to draft legislation addressing the over the counter drug monograph process including H.R.269, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 and H. R. 3443, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2019-07-16T11:49:18.487000-04:00
2304867,222bd1ca-71eb-4cba-95d5-ce032f3442d5,Q2,MCDERMOTT WILL & SCHULTE LLP,24338,"MAXOR NATIONAL PHARMACY SERVICES, LLC",2019,second_quarter,PHA,"Efforts to monitor and address pharmacy and drug pricing-related legislative and regulatory proposals, including, but not limited to, the 340B Program.","HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",30000,,0,0,2019-07-16T12:06:48.240000-04:00
2305079,2a0cf943-8a71-46d1-8dcb-4e56f4f9cc37,Q2,ISEMAN & ASSOCIATES LLC,401103582,"TICHENOR VENTURES, LLC",2019,second_quarter,PHA,Monitoring biotech legislation; prescription drug prices,"HOUSE OF REPRESENTATIVES,SENATE",12500,,0,0,2019-07-16T13:35:15.703000-04:00
2305327,134d4ff9-e515-40b0-ab30-55547aa7a2be,Q2,TAUZIN STRATEGIC NETWORKS,400786367,CAPTURERX,2019,second_quarter,PHA,Issues related to the 340b program,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2019-07-16T14:28:00.593000-04:00
2305449,afb6e336-7be2-4e14-b265-b09d403482d3,Q2,"BROWN & FORTUNATO, P.C.",401104878,"PROMPTCARE COMPANIES, INC.",2019,second_quarter,PHA,Issues related to Medicare home infusion therapy benefit and other health care issues.  Issues related to the Medicare DMEPOS competitive bidding program.,Centers For Medicare and Medicaid Services (CMS),12000,,0,0,2019-07-16T14:53:45.303000-04:00
2305492,73851b9a-8498-4d7d-9880-6df4cdc2c44c,Q2,"CONNECT 4 STRATEGIES, LLC",401103720,"FERRING PHARMACEUTICALS, INC.",2019,second_quarter,PHA,Medicare issues,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2019-07-16T15:05:00.477000-04:00
2305867,b0cbf4c6-e908-4d38-a3c4-217fc3800310,Q2,ELI LILLY AND COMPANY,13392,ELI LILLY AND COMPANY,2019,second_quarter,PHA,Hospital discounts; 340B program,"Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)",,2330000,0,0,2019-07-16T16:38:08.143000-04:00
2306510,cade41e7-bc5a-4510-8beb-e5120e149097,Q2,NATIONAL GROCERS ASSOCIATION,27924,NATIONAL GROCERS ASSOCIATION,2019,second_quarter,PHA,"Pharmacy DIR Fee Reform
Modernizing Part D and Medicare Advantage To Lower Drug Prices and Reduce Out-of-Pocket Expenses (CMS-4180-F)

H.R.1034 - Phair Pricing Act of 2019
S.640 - Phair Pricing Act of 2019
S.476 - Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019","Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Federal Reserve System,Federal Trade Commission (FTC),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE",,110000,0,0,2019-07-17T10:54:06.840000-04:00
2306686,a99c7619-6022-4bf3-a9c8-72b00a0c598c,Q2,THE ROTUNDA GROUP LLC,401104124,"MAGNA PHARMACEUTICALS, INC.",2019,second_quarter,PHA,illegal drug control policy,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2019-07-17T11:25:25.767000-04:00
2306841,bc97c245-2aeb-400a-9537-be730d37d02c,Q2,ZHF CONSULTING LLC,401103689,"MEDISCA, INC.",2019,second_quarter,PHA,Opioid crisis/alternative pain medication/including defense,,22500,,0,0,2019-07-17T11:51:11.943000-04:00
2306920,dba1c35c-76fc-455b-aa8e-238c29e6f25a,Q2,NATIONAL RURAL HEALTH ASSOCATION,53048,NATIONAL RURAL HEALTH ASSOCATION,2019,second_quarter,PHA,The 340B Program and drug pricing,"Agriculture, Dept of (USDA),HOUSE OF REPRESENTATIVES,SENATE",,16182,0,0,2019-07-17T12:08:35.570000-04:00
2307203,7a4307b4-b8f5-4e35-be19-216455ee40d9,Q2,"ALLERGAN USA, INC.",63837,"ALLERGAN USA, INC.",2019,second_quarter,PHA,Supporting proposals to strengthen safety standards and enforcement of the Drug Quality and Safety Act.,"Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",,1060000,0,0,2019-07-17T13:16:00.050000-04:00
2307246,a065be13-c491-4e6c-90f3-cc717aef4b5e,Q2,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN),2019,second_quarter,PHA,"Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 965 and S.340, the CREATES Act of 2019, and H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019.  Changes to the Risk Evaluation and Mitigation Strategies (REMS) program.  Reimbursement rate for biosimilars.  S. 1895, the Lower Health Care Costs Act.","HOUSE OF REPRESENTATIVES,SENATE,White House Office",60000,,0,0,2019-07-17T13:23:15.833000-04:00
2307555,295cd029-5684-4e30-b130-f32999bf622f,Q2,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CVS HEALTH,2019,second_quarter,PHA,"General education about the pharmacy benefit manager/pharmacy industry, including S.476, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU)Act.  Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.340 and H. R. 965, The CREATES Act.  S. 1895, Lower Health Case Costs Act; S.1227, The Prescription Pricing for the People Act of 2019.","HOUSE OF REPRESENTATIVES,SENATE,White House Office",60000,,0,0,2019-07-17T14:21:21.340000-04:00
2307658,632c0aea-1637-4f05-aeda-6292e7eda6bd,Q2,"BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.",6382,BLUE CROSS AND BLUE SHIELD OF FLORIDA INC,2019,second_quarter,PHA,"Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs; Rx Rebates; Direct to Consumer Rx Advertising; Biosimilars; Drug Approval

HR 965 (116th Congress), CREATES Act of 2019, by Rep. David Cicilline (D-RI).  To promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.

HR 1499 (116th Congress), Protecting Consumer Access to Generic Drugs Act of 2019, by Rep. Bobby Rush (D-IL).  To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.

HR 1503 (116th Congress), Orange Book Transparency Act of 2019, by Rep. Robin Kelly (D-IL).  To amend the Federal Food, Drug, and Cosmetic Act regarding the list under section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act, and for other purposes.

HR 1520 (116th Congress), Purple Book Continuity Act of 2019, by Rep. Anna Eshoo (D-CA).  To amend the Public Health Service Act to provide for the publication of a list of licensed biological products, and for other purposes.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office",,360000,0,0,2019-07-17T14:40:05.623000-04:00
2307669,5e61b84a-8855-4636-907c-75eaec60e71d,Q2,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,"GLENMARK PHARMACEUTICALS, INC., USA",2019,second_quarter,PHA,General information about the company and the industry.  Issues related to affordability and pricing of pharmaceuticals.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2019-07-17T14:41:09.140000-04:00
2307728,70660f97-568d-4ebd-bc39-ec7ec2c45a5b,Q2,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2019,second_quarter,PHA,N/A,"Commerce, Dept of (DOC),Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",,50000,0,0,2019-07-17T14:46:24.017000-04:00
2307741,30eef3e8-7aa1-40aa-8136-3e4b1cb14bcc,2A,"BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC.",6382,BLUE CROSS AND BLUE SHIELD OF FLORIDA INC,2019,second_quarter,PHA,"Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act; Drug Pricing; PBM/Prescription Drug Costs; Rx Rebates; Direct to Consumer Rx Advertising; Biosimilars; Drug Approval

HR 965 (116th Congress), CREATES Act of 2019, by Rep. David Cicilline (D-RI).  To promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.

HR 1499 (116th Congress), Protecting Consumer Access to Generic Drugs Act of 2019, by Rep. Bobby Rush (D-IL).  To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.

HR 1503 (116th Congress), Orange Book Transparency Act of 2019, by Rep. Robin Kelly (D-IL).  To amend the Federal Food, Drug, and Cosmetic Act regarding the list under section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act, and for other purposes.

HR 1520 (116th Congress), Purple Book Continuity Act of 2019, by Rep. Anna Eshoo (D-CA).  To amend the Public Health Service Act to provide for the publication of a list of licensed biological products, and for other purposes.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office",,370000,0,0,2019-07-17T14:47:25.483000-04:00
2307749,0cf13f50-de54-4b70-b484-974096164031,Q2,ACG ADVOCACY,2057,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2019,second_quarter,PHA,"Advocacy on Medicare and Medicaid pharmacy coverage and reimbursement issues. 
Advocating for coverage of pharmacists services under Medicare Part B. 
Advocating for the passage of legislation that curbs prescription drug abuse while protecting patient access to medication. 
Advocating for fair and accurate Medicaid pharmacy reimbursement. 
Advocating for Medicare Part D changes that increase beneficiary eligibility for medication therapy management.
Issues related to pharmacy reimbursement for 21st Century Cures.
Issues regarding TriCare coverage for pharmacies.
Issues regarding direct and indirect renumeration under Medicare Part D plans.","Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2019-07-17T14:49:28.843000-04:00
2307784,4ad9d4e5-84d5-4128-9794-c7adc04f0255,2A,ELI LILLY AND COMPANY,13392,ELI LILLY AND COMPANY,2019,second_quarter,PHA,Hospital discounts; 340B program,"Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)",,2330000,0,0,2019-07-17T14:56:44.390000-04:00
2307857,c0cce518-5866-4f11-94e9-a014d0b75f05,Q2,PRIME THERAPEUTICS,400339576,PRIME THERAPEUTICS,2019,second_quarter,PHA,"Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, provisions affecting market competition for prescription drugs and the drug supply chain.","HOUSE OF REPRESENTATIVES,SENATE",,83000,0,0,2019-07-17T15:07:03.857000-04:00
2308041,0f9d9d6d-0eb5-4b10-8c83-9803bdc51c8b,Q2,ACG ADVOCACY,2057,GENENTECH INC,2019,second_quarter,PHA,Drug Pricing Issues.,"Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2019-07-17T15:48:14.747000-04:00
2308084,a24953e9-d4d4-494e-991b-0914a4e98dff,Q2,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2019,second_quarter,PHA,"Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271)
Issues related to ARCOS data and suspicious order record requirements and reporting
Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844) Implementation of Public Law 113-54 (DSCSA)","Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,312426,0,0,2019-07-17T15:55:29.887000-04:00
2308121,2d1a07e6-dd70-4edf-b314-7d95f0caddeb,Q2,"OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC",30212,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2019,second_quarter,PHA,"Drug pricing, Direct and Indirect remuneration fees, Medicare","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2019-07-17T16:02:42.467000-04:00
2308436,47c0787f-c78c-45cc-9fdd-d7761415fd1b,Q2,ROCK & ASSOCIATES,33545,"BRAIDWOOD MANAGEMENT, INC.",2019,second_quarter,PHA,"H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2019-07-17T17:33:45.307000-04:00
2308449,4544c73b-aea9-455b-925a-23969f8a466c,Q2,ROCK & ASSOCIATES,33545,"VETERINARY PHARMACIES OF AMERICA, INC.",2019,second_quarter,PHA,"H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2019-07-17T17:41:48.530000-04:00
2308458,ea54e812-e7d2-4d25-a46f-a2c5954d81d5,Q2,ROCK & ASSOCIATES,33545,"WEDGEWOOD VILLAGE PHARMACY, INC.",2019,second_quarter,PHA,"H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019.","HOUSE OF REPRESENTATIVES,SENATE",22500,,0,0,2019-07-17T17:43:50.653000-04:00
2308464,69a285b5-cf3c-46ed-a5b9-5eb7add68885,Q2,ROCK & ASSOCIATES,33545,WOMEN'S INTERNATIONAL PHARMACY,2019,second_quarter,PHA,"H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2019-07-17T17:44:53.483000-04:00
2308468,a3aa16bc-48ce-4245-8e68-76e2510ad4b9,Q2,ROCK & ASSOCIATES,33545,WELLNESS PHARMACY,2019,second_quarter,PHA,"H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications.","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2019-07-17T17:46:54.217000-04:00
2308476,e461757f-9de3-45de-b9a2-f50db8f6017e,Q2,ROCK & ASSOCIATES,33545,PRECISION PHARMACY,2019,second_quarter,PHA,"H.R.1959, Preserving Patient Access to Compounded Medications Act of 2019. Also, FDA action on the Memorandum of Understanding (MOU) for human compounded medications. Also, potential FDA guidance on compounding from bulk ingredients for animal drug compounding.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2019-07-17T17:47:56.297000-04:00
2308594,178e3b54-776c-4251-8992-63487d524190,Q2,"GOVERNMENT COUNSEL, LLC",401105070,HEALTHCARE DISTRIBUTION ALLIANCE,2019,second_quarter,PHA,"Issues related to ARCOS data and suspicious order record requirements and reporting;importation of prescription drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844); implementation of Public Law 113-54 (DSCSA).","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2019-07-17T18:49:22.787000-04:00
2308793,4b653d06-8140-4259-b46d-c68d24d456cc,Q2,FIERCE GOVERNMENT RELATIONS,401103500,"SUN PHARMACEUTICAL INDUSTRIES, INC.",2019,second_quarter,PHA,"S. 340 - CREATES Act of 2019, Issues relating to biodefense, S. 64 - Preserve Access to Affordable Generics and Biosimilars Act",SENATE,60000,,0,0,2019-07-18T09:11:44.230000-04:00
2309176,80259229-38d2-496e-afc3-5a6d4800f92e,Q2,FIERCE GOVERNMENT RELATIONS,401103500,ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA),2019,second_quarter,PHA,"Issues relating to generic drugs, drug pricing, S. 340 - CREATES Act of 2019, Patent Abuse, S. 64- Preserve Access to Affordable Generics and Biosimilars Act, S. 1895- Lower Health Care Costs Act- Sec. 205, H.R. 965- CREATES Act of 2019","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2019-07-18T10:25:05.347000-04:00
2309476,0cfa618b-a27b-458d-a9da-fb09b3161b1e,Q2,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,27478,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,2019,second_quarter,PHA,"H.R. 1959, Preserving Patient Access to Compounded Medications Act of 2019;
H.R. 2376 / S. 1227, Prescription Pricing for the People Act of 2019;
H.R. 3223 / S. 1532, Pharmacy Benefit Manager Accountability Study Act of 2019;","Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),SENATE,Small Business Administration (SBA),Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office",,300000,0,0,2019-07-18T11:10:57.650000-04:00
2309750,5c16994e-5584-41a7-926f-19d533c8a504,Q2,BALLARD PARTNERS,401104288,LABORATORY CORPORATIONS OF AMERICA HOLDINGS,2019,second_quarter,PHA,Clinical Lab Rates,"Health & Human Services, Dept of (HHS),White House Office",80000,,0,0,2019-07-18T12:13:44.560000-04:00
2309985,0dcad4d7-b9c6-4a5d-8ff5-f84714f5a5fa,Q2,THE MCSWANE GROUP,401105094,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2019,second_quarter,PHA,direct and indirect remuneration (DIR) fee reform,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2019-07-18T13:10:14.473000-04:00
2310044,583b9c67-2212-424a-aac8-d7ba83aec7f8,2T,THE MCSWANE GROUP,401105094,NATIONAL ASSOCIATION OF CHAIN DRUG STORES,2019,second_quarter,PHA,direct and indirect remuneration (DIR) fee reform,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,1,2019-07-18T13:21:34.990000-04:00
2310162,e857a1fd-989b-4cd4-b0a6-589f7fe82f75,Q2,ASSOCIATION FOR ACCESSIBLE MEDICINES,16032,ASSOCIATION FOR ACCESSIBLE MEDICINES,2019,second_quarter,PHA,"Implementation of Food and Drug Administration Reauthorization Act (FDARA).
Generic Drug User Fee Amendments (GDUFA).
Biosimilar User Fee Act (BsUFA).
Labeling of Generic Drugs.
Drug Compounding.
Drug Shortages.
Biosimilars Naming.
Biosimilars Insulin.
Pass Through Payments for Biosimilars.
Prescription Drug Costs.
American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Proposed Anti-Kickback Statute (AKS) Rebates.
FDA Citizen Petitions.
H.R.985: FAST Generics Act of 2019.
H.R.1506: FAIR Generics Act.
H.R.1503: Orange Book Transparency Act of 2019.
H.R.1520: Purple Book Continuity Act of 2019.
S.61: Safe and Affordable Drugs from Canada Act of 2019.
S.64: Preserve Access to Affordable Generics and Biosimilars Act.
S.1416: Affordable Prescriptions for Patients Act of 2019.
S.1224: Stop STALLING Act.
H.R.447/S.97: Affordable and Safe Prescription Drug Importation Act.
S.124: Freedom to Compete Act.
H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019.
H.R.938: Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019.
H.R.465/S.102: Prescription Drug Price Relief Act of 2019.
H.R.1093/S. 378: Stop Price Gouging Act.
S.474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019.
S.475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019.
S.476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019.
S.440: Preserving Access to Cost Effective Drugs (PACED) Act.
S.1895: Lower Health Care Costs Act.
H.R.965/S.340: CREATES Act of 2019.
Public Law 115-123: Bipartisan Budget Act of 2018.
Risk Evaluation and Mitigation Strategies (REMS).
Pharmaceutical Exclusivity.
Biologic Exclusivity.
H.R.3379: Price Relief, Innovation, and Competition for Essential Drugs Act.
S.659: Biologic Patent Transparency Act.
Biologics Price Competition and Innovation Act (BPCIA).
Public Law 115-52: FDA Reauthorization Act of 2017.","Centers For Medicare and Medicaid Services (CMS),Commerce, Dept of (DOC),Congressional Budget Office (CBO),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Patent & Trademark Office (PTO),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)",,1100000,0,0,2019-07-18T13:49:22.430000-04:00
2310326,8d7e9dc8-cc4f-4549-8d24-a205b6304a86,Q2,BLUE CROSS AND BLUE SHIELD ASSOCIATION,6358,BLUE CROSS AND BLUE SHIELD ASSOCIATION,2019,second_quarter,PHA,"Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act;Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Direct-to-Consumer Rx Advertising;Rx Rebates; Biosimilars; Drug approval; 

H.R.1781 - 116th Congress (2019-2020)
Payment Commission Data Act of 2019
Sponsor: Rep. Carter, Earl L. ""Buddy"" [R-GA-1]
 
H.R.938 - 116th Congress (2019-2020)
BLOCKING Act of 2019
Sponsor: Rep. Schrader, Kurt [D-OR-5]

H.R.1520 - 116th Congress (2019-2020)
Purple Book Continuity Act of 2019
Sponsor: Rep. Eshoo, Anna G. [D-CA-18]

H.R.1503 - 116th Congress (2019-2020)
Orange Book Transparency Act of 2019
Sponsor: Rep. Kelly, Robin L. [D-IL-2] 

H.R.1499 - 116th Congress (2019-2020)
Protecting Consumer Access to Generic Drugs Act of 2019
Sponsor: Rep. Rush, Bobby L. [D-IL-1]

 H.R.965 - 116th Congress (2019-2020)
CREATES Act of 2019
Sponsor: Rep. Cicilline, David N. [D-RI-1]","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office",,1890000,0,0,2019-07-18T14:24:15.433000-04:00
2310422,2d54e5a8-fedd-417a-a4c6-52f9a94672ee,Q2,FARRAGUT PARTNERS LLP,401103938,COMMUNITY ONCOLOGY ALLIANCE,2019,second_quarter,PHA,Issues related to pharmacy benefit managers.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",80000,,0,0,2019-07-18T14:34:52.047000-04:00
2310451,e43e3b45-7fb7-408b-a0fd-b83c0b836f86,Q2,"KENT & O'CONNOR, INC.",21426,INTERNATIONAL WAREHOUSE LOGISTICS ASSOCIATION,2019,second_quarter,PHA,"Legislation and regulations relating to drug and safety issues.
Implementation of the Drug Supply Chain Security Act.","Environmental Protection Agency (EPA),Federal Maritime Commission,Food & Drug Administration (FDA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Occupational Safety & Health Administration (OSHA),SENATE,Surface Transportation Board (STB),Transportation, Dept of (DOT),Transportation Security Administration (TSA),Treasury, Dept of,U.S. Customs & Border Protection",30000,,0,0,2019-07-18T14:37:58.310000-04:00
2310461,55b547bb-14b0-4ff6-843f-895871ba828a,Q2,"MEHLMAN CONSULTING, INC.",284950,BLUE SHIELD OF CALIFORNIA,2019,second_quarter,PHA,Prescription drug pricing.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2019-07-18T14:39:01.763000-04:00
2310751,21e8acc5-c5be-48b9-8602-e8c112169878,Q2,"MEHLMAN CONSULTING, INC.",284950,AMERICA'S HEALTH INSURANCE PLANS,2019,second_quarter,PHA,Prescription drug pricing,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office",80000,,0,0,2019-07-18T15:04:35.110000-04:00
2311027,46134fc8-ae8b-43c9-bdff-00d04cb125f2,Q2,OREGON HEALTH & SCIENCE UNIVERSITY,30291,OREGON HEALTH & SCIENCE UNIVERSITY,2019,second_quarter,PHA,340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance.,"HOUSE OF REPRESENTATIVES,SENATE",,80000,0,0,2019-07-18T15:39:22.583000-04:00
2311045,54d0a8ca-7b2e-4726-b59e-74d2642860d9,Q2,PUBLIC CITIZEN,32362,PUBLIC CITIZEN,2019,second_quarter,PHA,"HR 1046/S 377-Medicare negotiation and competitive licensing act, HR 938-BLOCKING ACT, hr 965/s340- (creates ACT), HR 1503-Orange book transparency act, HR 1520-Purple book continuity act, HR 1499-Protecting consumer access to generic drugs act, S 64-preserve access to affordable generics and biosimilars act, drug pricing, HR 2113-Prescription drug STAR act, HR 1093/S 378 (Stop price gouging act, HR 1344-Competitive drugs act, HR 465/S 102-Prescription drug price relief act, HR-3379- PRICED act, affordable drug manufacturing act, S 1416-Affordable prescriptions to patients act,  HR 2374/S 1224 (stop STALLING act) HR 2917 Opioid Crisis accountability act, S 1209-REMEDY ACT, hr 6505 Medicare Negotiation and competitive Licensing act, SEC 101-Patent reform legislation","Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR)",,110000,0,0,2019-07-18T15:39:24.177000-04:00
2311365,3dca7968-ca8c-4d61-a1fc-4850dfc406eb,Q2,BLUE CROSS BLUE SHIELD OF MICHIGAN,46676,BLUE CROSS BLUE SHIELD OF MICHIGAN,2019,second_quarter,PHA,"Opioids (Epidemic, Deterrence, Economic Impact Zones); CREATES Act;Drug Pricing; PBM/Prescription Drug Costs Rx Rebates; Direct-to-Consumer Rx Advertising;Rx Rebates; Biosimilars; Drug approval; 

H.R.1520 - 116th Congress (2019-2020)
Purple Book Continuity Act of 2019
Sponsor: Rep. Eshoo, Anna G. [D-CA-18]

H.R.1503 - 116th Congress (2019-2020)
Orange Book Transparency Act of 2019
Sponsor: Rep. Kelly, Robin L. [D-IL-2] 

H.R.1499 - 116th Congress (2019-2020)
Protecting Consumer Access to Generic Drugs Act of 2019
Sponsor: Rep. Rush, Bobby L. [D-IL-1]

H.R.965 - 116th Congress (2019-2020)
CREATES Act of 2019
Sponsor: Rep. Cicilline, David N. [D-RI-1]","HOUSE OF REPRESENTATIVES,SENATE",,92595,0,0,2019-07-18T16:18:08.480000-04:00
2311969,6ac1a22d-eac9-4859-b163-89d2ad215a43,Q2,BROYDRICK & ASSOCIATES,7268,EXELA PHARMA SCIENCES,2019,second_quarter,PHA,Drug shortages and FDA approval. USTR acceptance.,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2019-07-18T21:31:09.363000-04:00
2312001,58d9be16-1b52-46ec-b3d6-9ce84f5472b7,Q2,BROYDRICK & ASSOCIATES,7268,TONIX PHARMACEUTICALS,2019,second_quarter,PHA,Funding new drug for PTSD.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2019-07-18T22:05:23.507000-04:00
2312037,2dc749ee-ef45-48a4-8892-124a1d16a698,Q2,FORGE FEDERAL AFFAIRS LLC,400865535,LILLY USA LLC,2019,second_quarter,PHA,"Issues related to pricing of prescription drugs.
Opposition to prescription drug importation and cuts to Medicare Part D funding.
Support for funding of Department of Homeland Security drug interdiction efforts.",HOUSE OF REPRESENTATIVES,20000,,0,0,2019-07-18T23:08:42.810000-04:00
2312170,ba03d842-659c-436d-aafa-c1e775dc4c85,Q2,VAN SCOYOC ASSOCIATES,39837,ZEBRA TECHNOLOGIES CORP.,2019,second_quarter,PHA,"Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation","HOUSE OF REPRESENTATIVES,SENATE",120000,,0,0,2019-07-19T05:24:33.583000-04:00
2312804,b39586e7-3a70-437a-9670-317f6870b008,Q2,FAEGRE BAKER DANIELS CONSULTING,34158,NATIONAL ASSOCIATION OF BOARDS OF PHARMACY,2019,second_quarter,PHA,Pharmacy regulation; Prescription drug monitoring,"Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE",110000,,0,0,2019-07-19T09:28:17.187000-04:00